Cargando…

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL

Detalles Bibliográficos
Autores principales:	Amatangelo, M., Cheng, Y., Pierceall, W., van de Donk, N. W., Lonial, S., Wang, M., Emerson, J., Hong, K., Maciag, P., Peluso, T., Gandhi, A., Thakurta, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430242/ http://dx.doi.org/10.1097/01.HS9.0000846340.95760.ac

Ejemplares similares

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: van de Donk, N. W. C. J, et al.
Publicado: (2022)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN-LABEL DOSE ESCALATION STUDY
por: van de Donk, N. W., et al.
Publicado: (2022)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
por: Furie, Richard A, et al.
Publicado: (2022)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
por: Tan, Carlyn, et al.
Publicado: (2023)

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways
por: Karagoz, Kubra, et al.
Publicado: (2022)

865. Acanthamoeba Disease Associated With the Practice of Nasal Rinsing in Immunocompromised Patients
por: Cope, Jennifer, et al.
Publicado: (2018)

High-Quality Draft Genome Sequence of Pseudomonas reidholzensis Strain CCOS 865(T)
por: Rutz, Dominik, et al.
Publicado: (2019)

P865: Revised letter of intent for a high - sensitivity study of charm and beauty decays
por: Isenhower, L D, et al.
Publicado: (1993)

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
por: Bjorklund, C C, et al.
Publicado: (2015)

Correction: Pacelli et al. Fully Automated, High-Dose Radiosynthesis of [18F]PARPi. Pharmaceuticals 2022, 15, 865
por: Pacelli, Anna, et al.
Publicado: (2023)

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus
por: Schafer, Peter H, et al.
Publicado: (2018)

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
por: Ye, Ying, et al.
Publicado: (2020)

Optimizing dosing in atypical neuroleptic monotherapy
por: Trémeau, Fabien, et al.
Publicado: (2002)

Elastic scattering of negative kaons on polarized protons between 865 and 1330 MeV/c
por: Albrow, Michael G, et al.
Publicado: (1971)

Polarization in elastic $\pi^{-}p$ scattering at 16 momenta between 865 and 2732 MeV/c
por: Albrow, M G, et al.
Publicado: (1972)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
por: Gleeson, Jack Patrick, et al.
Publicado: (2019)

High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system
por: Heim, Christopher, et al.
Publicado: (2022)

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
por: Cheng, Yiming, et al.
Publicado: (2023)

Healthberry 865(®) and a Subset of Its Single Anthocyanins Attenuate Oxidative Stress in Human Endothelial In Vitro Models
por: Ockermann, Philipp, et al.
Publicado: (2022)

865. Same Shift Susceptibility Testing of Cefepime-Taniborbactam and Cefiderocol Using The Selux Next-Generation Phenotyping System
por: Jimenez, David, et al.
Publicado: (2023)

Comparative VME Performance Tests for MEN A20 Intel-L865 and RIO-3 PPC-LynxOS platforms
por: Andersen, M, et al.
Publicado: (2009)

Association of response endpoints with survival outcomes in multiple myeloma
por: Lonial, S, et al.
Publicado: (2014)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

Prognostic Value of an Inflammation-Related Index in 6,865 Chinese Patients With Postoperative Digestive Tract Cancers: The FIESTA Study
por: Zhang, Xinran, et al.
Publicado: (2019)

POS-865 RENAL RECOVERY AFTER ACUTE KIDNEY INJURY ASSOCIATED TO COVID REQUIRING CONTINUOUS RENAL REPLACEMENT THERAPY DURING ICU HOSPITALIZATION
por: Pérez Hettinga, M.A., et al.
Publicado: (2022)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Smoking duration before first childbirth: an emerging risk factor for breast cancer? Results from 302,865 Norwegian women
por: Bjerkaas, Eivind, et al.
Publicado: (2013)

Epidemiology of haemodialysis catheter complications: a survey of 865 dialysis patients from 14 haemodialysis centres in Henan province in China
por: Wang, Kai, et al.
Publicado: (2015)

Genome Sequences of Bacillus thuringiensis Serovar kurstaki Strain BP865 and B. thuringiensis Serovar aizawai Strain HD-133
por: Jeong, Haeyoung, et al.
Publicado: (2017)

Minimizing complications in bikini incision direct anterior approach total hip arthroplasty: A single surgeon series of 865 cases
por: Alva, Avinash, et al.
Publicado: (2021)

865. Social Media Secret Facebook Groups for HIV Pre-Exposure Prophylaxis Awareness among Female Sex Workers in Cameroon
por: Guillamet, Laia Jimena Vazquez, et al.
Publicado: (2021)

DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD—Analysis of 10,865 Individuals
por: Tan, Caitlyn, et al.
Publicado: (2022)

Chemical shift assignments of calmodulin bound to the GluN1 C0 domain (residues 841–865) of the NMDA receptor
por: Bej, Aritra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n2s30e2291r4emp7unt73c4v42